

#### Unaudited financial statements

Statement of assets, liabilities, and partners' capital

Assets	
Investments, at fair value (cost \$11,906,776)	\$ 18,028,160
Cash	482,700
Interest receivable	4,653
Capital contributions receivable	181,132
Total assets	\$ 18,696,645
Liabilities and partners' capital	
Liabilities	
Due to related parties	\$ 886
Tax	14,285
Audit	13,400
Accrued expenses	27,685
Capital contributions received in advance	109,607
Accounts payable	7,050
Total liabilities	145,228
Partners' capital	
Total partners' capital	18,551,417
Total liabilities and partners' capital	\$ 18,696,645

#### Schedule of investments

Investments, at fair value	Invt. date	Shares	Cost	Fair value	Unrealized gain (loss)	Cost/s	hara	_	air value/share
	mivt. date	Silaies		raii vaiue	Omeanzed gam (1035)	Cost/s	liaic		all value/silate
Ares Materials, Inc.						_			
Series A Preferred	06/27/2019	9,921,946	\$ 1,500,000	\$ 1,500,000	\$ _	\$	0.15	\$	0.15
Biomakers, Inc.									
Series A-1 Preferred	01/26/2024	876,451	1,000,000	2,508,572	1,508,572		1.14		2.86
Compound Foods, Inc.			1,200,000	1,200,000	_		_		
SAFE	09/27/2020	_	200,000	200,000	_		_		_
SAFE	03/25/2021	_	1,000,000	1,000,000	_		_		_
Cubbo Holdings Limited									
Series Seed-1 Preferred	11/08/2021	856,245	900,000	1,982,514	1,082,514		1.05		2.32
DProtein Inc.			200,000	200,000	_		_		_
SAFE	07/23/2021	_	100,000	100,000	_		_		_
SAFE	11/15/2022	_	20,000	20,000	_		_		_
SAFE	05/18/2023	_	80,000	80,000	_		_		_
Encellin, Inc.									
Series Seed-1 Preferred	06/28/2019	1,357,632	1,250,000	2,539,994	1,289,994		0.92		1.87
Equator Therapeutics, Inc.									
SAFE	12/14/2021	_	500,000	500,000	_		_		_
Fiado, Inc.			750,000	750,000	_		_		
SAFE	08/03/2021	_	500,000	500,000	_		_		_
SAFE	10/29/2021	_	250,000	250,000	_		_		_

Schedule of investments (continued)

Investments, at fair value	Invt. date	Shares	Cost	Fair value	Unrealized gain (loss)	Cost	/share	Fair value/share
Finless Foods Inc.			\$ 480,979	\$ 613,259	\$ 132,280	\$	_	\$ _
Series A-3 Preferred	09/11/2020	336,020	245,093	377,373	132,280		0.73	1.12
Convertible Promissory Note	04/22/2024	_	235,886	235,886	_		_	_
GEn1E Lifesciences Inc.			1,000,000	2,342,725	1,342,725		_	_
Series Seed-3 Preferred	12/06/2022	520,724	500,000	924,760	424,760		0.96	1.78
Series Seed-4 Preferred	12/06/2022	798,466	500,000	1,417,965	917,965		0.63	1.78
Justo Inc.			889,635	846,981	(42,654)		_	_
Series C-1 Preferred	07/05/2024	538,939	241,995	241,995	_		0.45	0.45
Series C-2 Preferred	07/05/2024	1,347,348	647,640	604,986	(42,654)		0.48	0.45
Musa Technology, LLC								
Series A-2 Preferred	09/30/2021	702,350	304,118	1,261,280	957,162		0.43	1.80
PRIXZ, INC.								
Series A-1 Preferred	04/15/2022	62,988	1,000,000	1,000,000	_		15.88	15.88
Retail Integrated Ltd DBA 'Mercê	do Bairro'							
Series A Preference	09/02/2021	115,830	283,949	134,740	(149,209)		2.45	1.16
Torch Systems Inc.								
SAFE	11/10/2021	_	500,000	500,000	_		_	_
ZaxApp Holding Ltd.								
SAFE	12/22/2023	_	148,095	148,095	_		_	_
Total			\$ 11,906,776	\$ 18,028,160	\$ 6,121,384			

Schedule of investments (continued)

Asset type	Fair value as of September 30, 2024
Preferred stock	\$14,494,179
Convertible promissory note/SAFEs	3,533,981

#### Statement of operations

Investment income	
Portfolio interest income	\$ 4,653
Total interest income	4,653
Total investment income	4,653
Expenses	
Management fees	130,122
Tax preparation fees	14,790
Audit fees	13,400
Legal fees	10,730
Fund administration fees	6,250
Total professional fees	45,170
Other expenses	800
Total expenses	176,092
Net investment loss	(171,439)
Net change in unrealized gain (loss) on investments	
Net change in unrealized gain on investments	4,174
Net gain on investments	4,174
Net decrease in partners' capital from operations	\$ (167,265)

#### Statement of changes in partners' capital

	General Partner	Limited Partners	Total
Partners' capital, beginning of period	\$ 699,496	\$ 18,019,186	\$ 18,718,682
Capital contributions	18,848	560,190	579,038
Capital distributions	(18,848)	(560,190)	(579,038)
Management fees	_	(130,121)	(130,121)
Net operating income (loss)	(1,345)	(39,973)	(41,318)
Net unrealized gain (loss)	136	4,038	4,174
Partners' capital, end of period	\$ 698,287	\$ 17,853,130	\$ 18,551,417

#### Statement of cash flows

Cash, end of period	\$ 482,700
Cash, beginning of period	410,115
Net increase in cash	72,586
Net cash provided by financing activities	133,830
Capital distributions	(579,038)
Capital contributions	712,868
Cash flows from financing activities	
Net cash used in operating activities	(61,244)
Decrease in accounts payable	(229,636
Increase in accrued expenses	8,635
Decrease in due from related parties	800
Decrease in accounts receivable	577,043
Increase in interest receivable	(4,653
Changes in operating assets and liabilities:	
Purchase of investments	(241,994
Net change in unrealized gain on investments	(4,174
Adjustments to reconcile net decrease in partners' capital from operations to net cash used in operating activities:	
Net decrease in partners' capital from operations	\$ (167,265